Transthyretin cardiac amyloidosis was diagnosed in 9.8% of patients with cardioembolic stroke, with half of the cases remaining unrecognized until stroke presentation.
Cohort (n=143)
No
ATTR-CA is present in nearly 10% of patients with cardioembolic stroke, highlighting the need for systematic screening using echocardiography and troponin levels to identify candidates for disease-modifying therapies.
ATTR-CA was found in nearly 10% of elderly patients with cardioembolic stroke, with half remaining undiagnosed until stroke presentation. Cardiac hypertrophy, elevated troponin levels, and musculoskeletal manifestations provide practical screening indicators for stroke physicians. Given the availability of disease-modifying therapies, these findings emphasize the importance of systematic ATTR-CA screening in cardioembolic stroke populations.
Harada et al. (Mon,) conducted a cohort in Cardioembolic stroke (n=143). Transthyretin cardiac amyloidosis (ATTR-CA) vs. Non-cardiac amyloidosis was evaluated on Prevalence of ATTR-CA (95% CI 5.4-16.0). Transthyretin cardiac amyloidosis was diagnosed in 9.8% of patients with cardioembolic stroke, with half of the cases remaining unrecognized until stroke presentation.